New treatment options for alcohol use disorder
THERAPY FOR ALCOHOL USE DISORDER
This study is looking for new ways to help people with alcohol use disorder by testing new medications that can reduce drinking without causing unwanted side effects, and if you're interested, you might have the chance to join a clinical trial to see how well these new treatments work.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artiam Bio INC. NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project ID | NIH-10820349 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for alcohol use disorder (AUD), a condition affecting over 14 million adults in the US. The study aims to create second-generation cannabinoid receptor blockers that are effective in reducing alcohol consumption without causing adverse psychiatric effects, which were a concern with earlier treatments. By targeting the type 1 cannabinoid (CB1) receptor, the research seeks to maintain emotional well-being while minimizing relapse rates. Patients may participate in clinical trials to evaluate the safety and efficacy of these new compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over the age of 18 who are diagnosed with alcohol use disorder.
Not a fit: Patients who do not have alcohol use disorder or those who are not eligible for pharmacotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals struggling with alcohol use disorder.
How similar studies have performed: Previous research has shown promise in targeting cannabinoid receptors for treating substance use disorders, but this specific approach with second-generation blockers is novel.
Where this research is happening
Cary, United States
- Artiam Bio INC. — Cary, United States (Active)
Researchers
- Principal investigator: Seltzman, Herbert H — Artiam Bio INC.
- Study coordinator: Seltzman, Herbert H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.